Zai Lab (ZLAB) Stock Price

Zai Lab Price

NYSE·CLOSED
25.31
​
Market closed

Revenue has compounded at 221.6% per year over the past 7 years to 460.16 M USD. Zai Lab's net margin stands at -38.1%, up from -488.2% several years earlier. Analysts set a median price target of 52.50 USD, implying 107.4% above the current price. Of 15 analysts, 12 rate the stock a buy — an overall Buy consensus.

Zai Lab stock price

Access this data via the Eulerpool API

Zai Lab business model & stock analysis

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Frequently asked questions about Zai Lab

Analysts currently set an average price target of 53.75 USD for the Zai Lab stock (median: 52.50 USD), implying +112.4 % versus the latest price. The consensus is based on 15 analyst ratings.

15 analysts currently rate the Zai Lab stock: 12 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Zai Lab to generate revenue of 421.64 M USD and earnings per share of -2.26 USD.

Converted at the current exchange rate, the Zai Lab share trades at 22.60 EUR (25.31 USD).

The expected revenue of Zai Lab is 421.64 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Zai Lab is -249.77 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Zai Lab is currently -11.21. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Zai Lab stock.

The price-to-sales ratio (P/S) of Zai Lab is currently 6.64. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Zai Lab stock.

The Eulerpool Quality Score for Zai Lab is 4/10.

The ISIN of Zai Lab is US98887Q1040. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Zai Lab is A2DX1V. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Zai Lab is ZLAB. The ticker symbol is used to trade Zai Lab shares on the stock exchange.

Fair ValueTerminal
25.31 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
257,934.98 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Sep 20, 2017
ISIN
US98887Q1040
Cusip
98887Q104
Market capitalization
2.84 B USDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-11.21
P/Ee 2027
-11.60
P/Ee 2028
-17.39
P/Ee 2029
-124.37
P/Ee 2030
52.73
P/S
P/Se
6.64
EV/EBIT
—
P/B Ratio
3.97
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-18.95 %
Last updated Oct 8, 2026, 5:17 AM

Zai Lab Peer Group

All fundamentals and in-depth analysis of Zai Lab

Our stock analysis for Zai Lab stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zai Lab. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.